HealthDay News – Use of pantoprazole for up to 3 years to prevent upper gastrointestinal events in patients receiving anticoagulant therapy with aspirin and/or rivaroxaban has a similar safety profile to placebo except for an increased risk for enteric infections, according to a study published online May 29 in Gastroenterology.

Paul Moayyedi, MB, ChB, PhD, from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted a three-by-two partial factorial, multicenter, double-blind, randomized placebo-controlled trial evaluating patients with stable atherosclerotic vascular disease. Participants were randomly assigned to receive rivaroxaban (2.5mg twice daily) with aspirin (100mg once daily), rivaroxaban (5mg twice daily) alone, or aspirin (100mg) alone. In addition, 17,598 participants were randomly assigned to receive either pantoprazole (40mg daily; 8791 participants) or placebo (8807 participants).

The researchers noted no statistically significant difference between the pantoprazole and placebo groups regarding safety events, except for enteric infections (1.4% with pantoprazole versus 1.0% with placebo; odds ratio, 1.33). Additionally, Clostridium difficile infection was approximately twice as common in the pantoprazole group versus the placebo group. However, with only 13 events, this difference was not statistically significant.

Related Articles

“Our research provides welcomed news for the countless patients who rely on PPIs to control their symptoms, as well as the physicians who prescribe this medication,” Moayyedi said in a statement.

Bayer funded the study. Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, the manufacturer of pantoprazole.

Abstract/Full Text (subscription or payment may be required)